Implementation of TIL therapy in Ovarian Cancer

Impact: Health impacts


TIL therapy, in which tumour infiltrating are extracted from tumour, expanded ex vivo and reinfused back to the patient as an autologous treatment, has the potential to revolutionise treatment. Treatment is not without challenges, and trials needed to be preceded by demonstration of biological feasibility and infrastructure development including links with commercial partners.
We have undertaken an extensive programme to demonstrate clinical feasibility of the use of non engineered T cells and have developed a strong collaboration between the university, two local NHS trusts and 9 commercial partners (iMATCH, INNOVATE UK £9M) resulting in the award of funding to run the first trial of TIL therapy in ovarian cancer in the UK (INNOVATE UK, £3M).

Category of impact

  • Health impacts